California
Biotech Insights

Recent Funding: cAMPfield Therapeutics (SD) Launches with $180 Million Series A to Develop Licensed Inflammatory Disease Drugs cAMPfield Therapeutics has quietly secured $180 million in backing from a powerhouse group of investors including Novo Holdings, RA Capital, Frazier Life Sciences, and Venrock — following the increasingly popular model of building a company around drugs licensed […]

M&A, Deals, Partnerships: Quince Therapeutics (SF) Merges with Private Pulmonary Startup to Stay Alive on Nasdaq After its lead drug for a rare childhood neurological disease failed in a Phase 3 trial earlier this year, cash-strapped Quince Therapeutics is merging with private pulmonary startup Orphai Therapeutics in an all-stock deal that will keep the combined […]

Recent Funding: Artiva Biotherapeutics (SD) Reports 71% Response Rate in Rheumatoid Arthritis Trial and Raises $300 Million Artiva’s off-the-shelf NK cell therapy AlloNK plus rituximab achieved a 71% ACR50 response (meaningful symptom improvement) in refractory rheumatoid arthritis patients at six months—dramatically outperforming the 11-19% response rate seen with current therapies in this difficult-to-treat population of […]

M&A, Deals, Partnerships: Protagonist Therapeutics (SF) Opts for $475 Million Payout Over U.S. Profit Split with Takeda Protagonist is cashing out its U.S. co-promotion rights for rusfertide — a drug for a rare blood disorder called polycythemia vera — taking $200 million now and another $275 million if the FDA approves the drug, expected later […]

Recent Funding: Ray Therapeutics (SF) Raises $125 Million to Advance Gene Therapy for Vision Loss Ray Therapeutics closed an oversubscribed Series B round led by Janus Henderson Investors to fund its lead gene therapy RTx-015, which aims to restore vision in patients with retinitis pigmentosa — a genetic disease that progressively destroys the cells in […]